ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

HIK Hikma Pharmaceuticals Plc

1,918.50
38.00 (2.02%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals Plc LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  38.00 2.02% 1,918.50 1,925.00 1,927.00 1,937.50 1,887.50 1,903.00 504,022 16:35:27
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 2.88B 190M 0.8594 22.41 4.26B
Hikma Pharmaceuticals Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HIK. The last closing price for Hikma Pharmaceuticals was 1,880.50p. Over the last year, Hikma Pharmaceuticals shares have traded in a share price range of 1,614.50p to 2,222.00p.

Hikma Pharmaceuticals currently has 221,081,676 shares in issue. The market capitalisation of Hikma Pharmaceuticals is £4.26 billion. Hikma Pharmaceuticals has a price to earnings ratio (PE ratio) of 22.41.

Hikma Pharmaceuticals Share Discussion Threads

Showing 201 to 223 of 1875 messages
Chat Pages: Latest  15  14  13  12  11  10  9  8  7  6  5  4  Older
DateSubjectAuthorDiscuss
12/1/2015
15:12
Hikma is featured into today's ADFVN podcast.

To listen to the podcast click here>

In today's podcast:

- Technical Analyst Nicola Duke will be chatting and charting, Anite, Big Yellow Group, ITE, Union Jack Oil, Afren. Nicola on Twitter is @NicTrades

- And the micro and macro news including:

Quindell #QPP
Afren #AFR
Shire #SHP
ITV #ITV
Taylor Wimpey #TW.
Big Yellow Group #BYG
ITE #ITE
Union Jack Oil #UJO
Anite #AIE
Unite Group #UTG
Pace #PIC
Royal Mail #RMG
Prudential #PRU
Hikma Pharmaceuticals #HIK
AO World #AO.
Betfair #BET
Sound Oil #SOU
Advanced Oncotherapy #AVO
International Airlines Group #IAG
Afren #AFR
Ophir Energy #OPHR
Premier Farnell #PFL
New River Retail #NRR
Victrex #VCT
Catlin Group #CGL

Every Tuesday is Ten Bagger Tuesday on the podcast. If you know of a stock, whose share price has the potential to increase ten fold, just click the link below.



(All it involves is filling out a form that will take you around 5 minutes and you don't personally appear on the podcast).

Once a week, on a Friday, I feature a tip from a listener to this podcast, if you'd like to suggest a stock click the link below:



(Again all it involves is filling out a form that will take you around 5 minutes and you don't personally appear on the podcast).

You can subscribe to this podcast in iTunes by clicking

To follow me on Twitter click

As a listener to the ADVFN podcast you can take advantage of some exclusive first year discounts on popular subscriptions:

Bronze - £50 (normally £73.82/year)
Silver - £145 (normally £173.71/year)
Level 2 - £350 (normally £472.94/year)

Call 0207 0700 961 and ask for the ADVFN Podcast discount to take advantage of these reduced rates or just for more information.

Please DO NOT buy any stock recommended in this podcast basely solely on what you hear. The opinions in this podcasts are just that, opinions. Please do you own research before investing.

Justin

 

 

jeffcranbounre
12/1/2015
09:29
Yep, looks like FTSE entry.

Takeover activity in the sector today.

broadwood
09/1/2015
14:57
ftse100 entry is looking good short term.
pyemckay
09/1/2015
13:56
nothing else is there?
r ball
09/1/2015
13:11
Strong Buy majority of Brokers who cover .
broadwood
05/1/2015
15:42
Hikma is mentioned in today's (05/01/15) ADVFN podcast.

To listen to the podcast click here>


In today's podcast:

- Nicola Duke technical analyst dicusses Quindell, Sainsburys, TERN and BP. Nicola on Twitter is @NicTrades

- And the micro and macro news including:

Quindell #QPP
Tesco #TSCO
Lloyds #LLOY
TERN #TERN
Asda
Gulf Keystone Petroleum #GKP
BP #BP.
Rockhopper Exploration #RKH
Galliford Try #GFRD
Xaar #XAR
PureCircle #PURE
Hikma Pharmaceuticals #HIK
AstraZeneca #AZN
GlaxoSmithKline #GSK
Marks & Spencer #MKS
Sainsbury #SBRY

Every Tuesday is Ten Bagger Tuesday on the podcast. If you know of a stock, whose share price has the potential to increase ten fold, just click the link below.



(All it involves is filling out a form that will take you around 5 minutes and you don't personally appear on the podcast).

Once a week, on a Friday, I feature a tip from a listener to this podcast, if you'd like to suggest a stock click the link below:



(Again all it involves is filling out a form that will take you around 5 minutes and you don't personally appear on the podcast).

You can subscribe to this podcast in iTunes by clicking

To follow me on Twitter click

As a listener to the ADVFN podcast you can take advantage of some exclusive first year discounts on popular subscriptions:

Bronze - £50 (normally £73.82/year)
Silver - £145 (normally £173.71/year)
Level 2 - £350 (normally £472.94/year)

Call 0207 0700 961 and ask for the ADVFN Podcast discount to take advantage of these reduced rates or just for more information.

Please DO NOT buy any stock recommended in this podcast basely solely on what you hear. The opinions in this podcasts are just that, opinions. Please do you own research before investing.

Justin

 

 

jeffcranbounre
05/1/2015
08:54
Upgraded by Jeffries.

New TP 2325.

broadwood
05/12/2014
22:46
FLASH: Panmure Gordon stays hold on Hikma, target raised to 2,120p from 1,800p4 December 2014 | 12:23pmStockMarketWire.com -- See more at:
coppertrader
02/12/2014
17:10
Too true, hikma seems to be under the radar of many despite rising steadily for many years. As of last friday they were placed 98th on a market cap of 3893m. They only need to get their market cap to above morrisons current market cap of 4168m to be in 89th place and get automatic entry. About 7% rise from their current position.
coppertrader
02/12/2014
14:12
Hikma Pharmaceuticals

Hikma Pharmaceuticals was founded in 1978, and floated on the London stock exchange in 2005 with a market capitalisation of £480m. In less than 10 years, Hikma has grown into a £3.9bn company and is now poised just below the threshold for entry into the FTSE 100.

Hikma operates through three businesses (branded, generics and injectables) and is a market leader in the Middle East and North Africa (MENA) region. Hikma trades on a deserved premium P/E of 22 at a share price of 1,964p, and has the financial resources to make strategic acquisitions and investments that could rapidly lift the company into the FTSE 100.

Hikma’s strong position in the MENA region also makes the company attractive to US and European drugs players. A bid (or rumours of one) could be another catalyst for catapulting Hikma’s valuation through the FTSE 100 entry level.

broadwood
06/11/2014
11:24
- Hikma Pharmaceuticals reports a strong performance in its Injectables, Branded and Generics businesses and has raised its guidance for 2014 group revenue growth of around 7%. The group says its financing position remains very strong and will enable it to make further strategic acquisitions and investments, as opportunities arise. Chairman and chief executive Said Darwazah said: "I am pleased with how our businesses are performing this year. The continued strength of our Injectables business reflects the benefit of our broad portfolio and our success in capturing market opportunities. "The Generics business continues to perform extremely well this year and we are focused on developing our portfolio and pipeline to support future growth. "The Branded business is delivering good growth in a number of important markets and we believe the actions we are taking to restructure our business in Algeria and our commitment to operating in markets impacted by political disruptions, will strengthen our business for the future. " An interim management statement said: "Our global Injectables business is performing well, as we continue to capture specific market opportunities in the US. Competition is increasing in the US and we expect underlying sales in the second half to be broadly in line with the first half of the year. In MENA, we are seeing a good performance and are on track to deliver slight growth for the full year, while European contract manufacturing sales remain lower this year. Due to the continued strength of specific market opportunities, we are raising our guidance to around 25% revenue growth in 2014, with an adjusted operating margin of above 35%. "Following our acquisition of Bedford Laboratories in July, we also completed the acquisition of the Ben Venue manufacturing site in Bedford, Ohio in September. This will significantly enhance our R&D capabilities and enable us to expand future capacity for injectables manufacturing. "As previously announced, in October 2014 we received a warning letter from the US Food and Drug Administration ("FDA") related to the inspection of our manufacturing facility in Portugal in March 2014. We will work with the FDA to fully resolve all outstanding issues as quickly as possible. "Revenue in our Branded business is broadly in line with last year. We are delivering good growth in markets such as Egypt and the Gulf Cooperation Council ("GCC") countries, including Saudi Arabia, driven by our strategic focus on newer, higher value products. However, this is being offset by the ongoing restructuring of our business in Algeria and political disruptions, primarily in Iraq and Libya. Overall, we continue to expect the Branded business to deliver low single digit revenue growth for the full year, with an adjusted operating margin of around 21%. "The Generics business continues to perform very strongly this year, reflecting specific market opportunities and the re-introduction of products. We now expect the Generics business to deliver revenue of around $215 million in 2014, with an adjusted operating margin of around 55%. "On 30 September 2014, we received an approval for a New Drug Application for colchicine 0.6mg capsules by the US FDA, under Section 505(b)(2) of the US Federal Food Drug and Cosmetic Act. On 9 October, the US District Court for the District of Delaware granted Takeda Pharmaceuticals U.S.A., Inc. ("Takeda") a temporary restraining order while the court considered a motion by Takeda for a preliminary injunction. On 5 November, the court denied Takeda's motion but extended the temporary restraining order pending appeal. Our guidance for 2014 does not reflect any contribution from colchicine -
broadwood
06/11/2014
07:44
Hikma Pharmaceuticals raises revenue guidance
broadwood
06/11/2014
07:35
price rise yesterday due to results anticipation or court ruling?
r ball
05/11/2014
17:00
IMS tomorrow.
broadwood
05/11/2014
14:35
At your peril.
broadwood
05/11/2014
13:32
a share to ignore.
r ball
05/11/2014
13:32
a share to ignore.
r ball
10/10/2014
11:17
litigation! boo
pyemckay
10/10/2014
00:26
HIK. is now approx 97th ranked by market cap in ftse now, It needs to make position 90 to get into ftse 100 which would give it another audience for its shares.

Its only a matter of time now but with markets falling and hikma still advancing it could come sooner than later.

pyemckay
03/10/2014
07:18
Sold my shares in HIK. Reason being that I've held for about a year and therefore made 50% but now look at those profits as being at risk given (1) market conditions and (2) the next couple year forecasts for HIK suggesting zero earnings growth (or less) but a >22x PE. The combination of that multiple and growth suggests limited upside to me over the next couple years so better to bank a profit.
All the best for those who continue to hold

adamb1978
01/10/2014
07:57
no reason to sell.
r ball
01/10/2014
06:33
Yep, just seen it.

Hikma Pharmaceuticals has received approval of its new drug application for colchicine 0.6mg capsules by the US Food and Drug Administration. Hikma will market its colchicine under the brand name MITIGARE. MITIGARE is indicated for prophylaxis of gout flares in adults. This NDA has been approved under section 505(b)(2) of the US Federal Food Drug and Cosmetic Act. Hikma chairman and chief executive Said Darwazah said: "This approval demonstrates our strong regulatory capabilities and the successful execution of our strategy to develop a more differentiated product portfolio for the US market

broadwood
30/9/2014
17:16
FDA APPROVAL FOR COLCHICINE
mirabeau
Chat Pages: Latest  15  14  13  12  11  10  9  8  7  6  5  4  Older

Your Recent History

Delayed Upgrade Clock